Company Update: Pfizer Inc (NYSE:PFE) – Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

[PR Newswire] – BALTIMORE, Aug. 10, 2015 /PRNewswire/ — Gliknik Inc. , a privately held biopharmaceutical company, today announced that its licensee Pfizer Inc. (NYSE: PFE) has received notification from the U.S. Food . . . → Read More: Company Update: Pfizer Inc (NYSE:PFE) – Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder Similar Articles: Stock Update (NYSE:PFE): Britain raps Pfizer over inflated epilepsy drug prices Market Update: Pfizer Inc (NYSE:PFE) – Exclusive: Pfizer is mystery bidder for rare disease drugmaker Sobi – sources Company Update (NYSE:PFE): Pfizer, Lilly to resume late-stage study testing pain drug